These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 25324145)
1. [Ketamine as antidepressant: the current study situation]. Ritter PS; Bauer M; Pilhatsch M Nervenarzt; 2014 Nov; 85(11):1432-5. PubMed ID: 25324145 [TBL] [Abstract][Full Text] [Related]
2. Comparison of antidepressant and side effects in mice after intranasal administration of (R,S)-ketamine, (R)-ketamine, and (S)-ketamine. Chang L; Zhang K; Pu Y; Qu Y; Wang SM; Xiong Z; Ren Q; Dong C; Fujita Y; Hashimoto K Pharmacol Biochem Behav; 2019 Jun; 181():53-59. PubMed ID: 31034852 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1). Fedgchin M; Trivedi M; Daly EJ; Melkote R; Lane R; Lim P; Vitagliano D; Blier P; Fava M; Liebowitz M; Ravindran A; Gaillard R; Ameele HVD; Preskorn S; Manji H; Hough D; Drevets WC; Singh JB Int J Neuropsychopharmacol; 2019 Oct; 22(10):616-630. PubMed ID: 31290965 [TBL] [Abstract][Full Text] [Related]
4. Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program. Doherty T; Wajs E; Melkote R; Miller J; Singh JB; Weber MA CNS Drugs; 2020 Mar; 34(3):299-310. PubMed ID: 31994024 [TBL] [Abstract][Full Text] [Related]
6. Ketamine and depression: a narrative review. Corriger A; Pickering G Drug Des Devel Ther; 2019; 13():3051-3067. PubMed ID: 31695324 [TBL] [Abstract][Full Text] [Related]
7. Dissociating the Clinical Role and Economic Value of Intranasal Esketamine. Dadiomov D J Manag Care Spec Pharm; 2020 Jan; 26(1):20-22. PubMed ID: 31880233 [TBL] [Abstract][Full Text] [Related]
8. Breaking Sad: Unleashing the Breakthrough Potential of Ketamine's Rapid Antidepressant Effects. Feifel D Drug Dev Res; 2016 Dec; 77(8):489-494. PubMed ID: 27888525 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial. Daly EJ; Singh JB; Fedgchin M; Cooper K; Lim P; Shelton RC; Thase ME; Winokur A; Van Nueten L; Manji H; Drevets WC JAMA Psychiatry; 2018 Feb; 75(2):139-148. PubMed ID: 29282469 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. Daly EJ; Trivedi MH; Janik A; Li H; Zhang Y; Li X; Lane R; Lim P; Duca AR; Hough D; Thase ME; Zajecka J; Winokur A; Divacka I; Fagiolini A; Cubala WJ; Bitter I; Blier P; Shelton RC; Molero P; Manji H; Drevets WC; Singh JB JAMA Psychiatry; 2019 Sep; 76(9):893-903. PubMed ID: 31166571 [TBL] [Abstract][Full Text] [Related]
11. Ketamine augmentation for outpatients with treatment-resistant depression: Preliminary evidence for two-step intravenous dose escalation. Cusin C; Ionescu DF; Pavone KJ; Akeju O; Cassano P; Taylor N; Eikermann M; Durham K; Swee MB; Chang T; Dording C; Soskin D; Kelley J; Mischoulon D; Brown EN; Fava M Aust N Z J Psychiatry; 2017 Jan; 51(1):55-64. PubMed ID: 26893373 [TBL] [Abstract][Full Text] [Related]
13. Glutamatergic Signaling Drives Ketamine-Mediated Response in Depression: Evidence from Dynamic Causal Modeling. Gilbert JR; Yarrington JS; Wills KE; Nugent AC; Zarate CA Int J Neuropsychopharmacol; 2018 Aug; 21(8):740-747. PubMed ID: 29668918 [TBL] [Abstract][Full Text] [Related]
14. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study. Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208 [TBL] [Abstract][Full Text] [Related]
15. Ketamine for Depression, 3: Does Chirality Matter? Andrade C J Clin Psychiatry; 2017 Jun; 78(6):e674-e677. PubMed ID: 28682536 [TBL] [Abstract][Full Text] [Related]
16. Intranasal esketamine: A novel drug for treatment-resistant depression. Khorassani F; Talreja O Am J Health Syst Pharm; 2020 Aug; 77(17):1382-1388. PubMed ID: 32729898 [TBL] [Abstract][Full Text] [Related]
17. Ketamine Treatment for Depression in Patients With a History of Psychosis or Current Psychotic Symptoms: A Systematic Review. Veraart JKE; Smith-Apeldoorn SY; Spijker J; Kamphuis J; Schoevers RA J Clin Psychiatry; 2021 Jul; 82(4):. PubMed ID: 34255943 [No Abstract] [Full Text] [Related]
18. Assessment of Relationship of Ketamine Dose With Magnetic Resonance Spectroscopy of Glx and GABA Responses in Adults With Major Depression: A Randomized Clinical Trial. Milak MS; Rashid R; Dong Z; Kegeles LS; Grunebaum MF; Ogden RT; Lin X; Mulhern ST; Suckow RF; Cooper TB; Keilp JG; Mao X; Shungu DC; Mann JJ JAMA Netw Open; 2020 Aug; 3(8):e2013211. PubMed ID: 32785636 [TBL] [Abstract][Full Text] [Related]
19. Ketamine as a new treatment for depression: a review of its efficacy and adverse effects. Katalinic N; Lai R; Somogyi A; Mitchell PB; Glue P; Loo CK Aust N Z J Psychiatry; 2013 Aug; 47(8):710-27. PubMed ID: 23661785 [TBL] [Abstract][Full Text] [Related]
20. Intravenous ketamine for treatment-resistant major depressive disorder. Covvey JR; Crawford AN; Lowe DK Ann Pharmacother; 2012 Jan; 46(1):117-23. PubMed ID: 22190250 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]